Introduction to the market situation of ponatinib/ponatinib in India and its purchase channels, prices and precautions for use

Ponatinib (ponatinib) is an oral small molecule tyrosine kinase inhibitor (TKI), mainly used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and acute lymphoblastic leukemia (Ph+ ALL) patients, especially for patients who are resistant or intolerant to other tyrosine kinase inhibitors. Its mechanism of action is by inhibiting the tyrosine kinase activity of the BCR-ABL fusion protein, thereby blocking the proliferation and survival signals of leukemia cells.

In the Indian market, there are no generic drugs of ponatinib, so patients can only obtain it through the original drug or specific channels. Since it has not yet been launched in China, the drug's accessibility to Chinese patients mainly relies on overseas channels. In the overseas market, the Hong Kong original version of ponatinib is priced at approximately more than 17,000 yuan per box, while the Laos and Bangladeshi versions of the generic drugs are more affordable, ranging from more than 700 yuan to more than 1,000 yuan respectively. Generic drugs are basically the same as the original drugs in terms of ingredients, providing an alternative for patients with limited budgets.

In terms of purchasing channels, generic drugs in India and other regions are mainly obtained through local regular pharmacies or cross-border medical channels. During use, patients should ensure that the source of drugs is reliable and avoid purchasing unapproved drugs from informal channels to avoid affecting the efficacy or causing safety issues. In addition, imported drugs are subject to relevant laws and regulations, including customs declaration and prescription requirements.

When using ponatinib, attention should be paid to individualized dose adjustment and adverse reaction management. Common adverse reactions include hematological abnormalities, rash, diarrhea, and thrombotic events. Therefore, blood routine, liver and kidney function, and cardiovascular indicators should be regularly monitored before and during treatment. Patients should follow the doctor's instructions while taking the medicine, avoid stopping the medicine on their own or adjusting the dosage at will, and cooperate with the doctor for follow-up to ensure the maximum efficacy and safety of the medicine.

Keyword tag:

TKIinhibitors, chronic myelogenous leukemia (CML), Ph+ ALL, drug-resistant mutations, imported drugs, generic drugs, drug prices, regular drug purchase channels

Reference materials:https://pubmed.ncbi.nlm.nih.gov/29029002/